Show simple item record

dc.contributor.authorHalcox, Julian P.
dc.contributor.authorTubach, Florence
dc.contributor.authorLopez-Garcia, Esther
dc.contributor.authorDe Backer, Guy
dc.contributor.authorBorghi, Claudio
dc.contributor.authorDallongeville, Jean
dc.contributor.authorGuallar, Eliseo 
dc.contributor.authorMedina, Jesus
dc.contributor.authorPerk, Joep
dc.contributor.authorSazova, Oguen
dc.contributor.authorSweet, Stephen
dc.contributor.authorRoy, Carine
dc.contributor.authorBanegas, José Ramón
dc.contributor.authorRodríguez-Artalejo, Fernando
dc.date.accessioned2017-12-01T07:37:25Z
dc.date.available2017-12-01T07:37:25Z
dc.date.issued2015
dc.identifierISI:000350061500007
dc.identifier.citationPLoS One. 2015 Feb 18;10(2):e0115270
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/20.500.12105/5516
dc.description.abstractAims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. Methods and Results Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which included a randomly sampled population of primary CVD prevention patients from 12 European countries (n = 7641). Patients' 10-year risk of CVD-related mortality was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019 patients at high cardiovascular risk (SCORE >= 5\% and/or receiving lipid-lowering therapy), and 2970 patients at very high cardiovascular risk (SCORE >= 10\% or with diabetes mellitus). Among high-risk individuals, 65.3\% were receiving lipid-lowering therapy, and 61.3\% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels (>= 2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as >= 1.8 mmol/L) these figures were 49.5\% and 82.9\%, respectively. Excess 10-year risk of CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia was estimated to be 0.72\% and 1.61\% among high-risk and very-high-risk patients, respectively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7\% were receiving a high-intensity statin (atorvastatin >= 40 mg/day or rosuvastatin >= 20 mg/day). Among very-high-risk patients, this figure was 8.4\%. Conclusions There is a considerable opportunity for improvement in rates of lipid-lowering therapy use and achievement of lipid-level targets in high-risk and very-high-risk patients being treated for primary CVD prevention in Europe.
dc.description.sponsorshipThe EURIKA study was funded by AstraZeneca. The study was run by an independent academic steering committee, which worked under rules agreed a priori that allowed intellectual input of the funder (i.e. the funder contributed ideas to the study design, data analysis and preparation of the manuscript) while granting the executive and decision making role to the committee. The authors had full access to all data and had final responsibility for the contents of the manuscript and the decision to submit it for publication. Writing support was provided by Oxford PharmaGenesis Ltd, Oxford, UK, and was funded by AstraZeneca.
dc.language.isoeng
dc.publisherPUBLIC LIBRARY SCIENCE
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectRANDOMIZED-TRIALS
dc.subjectADULT-POPULATION
dc.subjectPREVALENCE
dc.subjectMANAGEMENT
dc.subjectMETAANALYSIS
dc.subjectPREVENTION
dc.subjectPROJECT
dc.subjectSTATINS
dc.subjectEURIKA
dc.subjectSPAIN
dc.titleLow Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe
dc.typeArtículo
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID25692692
dc.format.volume10
dc.identifier.doi10.1371/journal.pone.0115270
dc.contributor.funderAstraZeneca
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0115270
dc.identifier.journalPLOS ONE
dc.identifier.journalPLoS One. 2015 Feb 18;10(2):e0115270.
dc.repisalud.orgCNICCNIC::Grupos de investigación::Antiguos CNIC
dc.repisalud.institucionCNIC
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional